Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201498 | 0.82 | NPC1 (0.47) | MAOBNPC1RAB9ACCR5HDAC8 | |
| SCHEMBL21178440 | 0.77 | P2RY12 (0.46) | RAB9ACCR5MAPTAPPCSF1R | |
| SCHEMBL21187309 | 0.74 | KIT (0.44) | MAOBNPC1RAB9ACCR5HDAC8 | |
| SCHEMBL20521768 | 0.74 | NPC1 (0.54) | MAOBNPC1RAB9AMAPTCSF1R | |
| SCHEMBL21179008 | 0.73 | CSF1R (0.41) | MAOBNPC1RAB9ACCR5HDAC8 | |
| SCHEMBL25180595 | 0.73 | CCR5 (0.57) | MAOBNPC1RAB9ACCR5APP | |
| SCHEMBL30823299 | 0.72 | PDE2A (0.43) | MAOBNPC1RAB9ACCR5HDAC8 | |
| SCHEMBL21177909 | 0.72 | PDE2A (0.43) | MAOBNPC1RAB9ACCR5HDAC8 | |
| SCHEMBL30682049 | 0.72 | CCR5 (0.56) | MAOBCCR5APPCSF1RNTRK1 | |
| SCHEMBL189978 | 0.71 | MAOB (0.47) | MAOBNPC1RAB9ACCR5HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-20210060028-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-03-04 | — | — | US | disclosed |
| EP-3740479-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019143675-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143675-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | MAOB 3026/4885NPC1 706/4885RAB9A 4183/4885 |
| US-20210060028-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAOB 3026/4885NPC1 706/4885RAB9A 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.